How the FDA Pharmacy Compounding Advisory Committee (PCAC) Works

What PCAC is

The Pharmacy Compounding Advisory Committee (PCAC) advises FDA on compounding-related scientific and regulatory questions, including whether nominated bulk drug substances should be recommended for addition to the Section 503A Bulk Drug Substances List.

Meetings are announced in the Federal Register. FDA publishes agendas and briefing documents so the public can follow the topics under review.

Who sits on the committee

The standing roster typically mixes clinical, pharmacy, and standards expertise. FDA’s published membership materials list seats such as clinical research, regenerative medicine practice, pharmacy operations, USP representation, and NABP representation, plus a non-voting industry representative. Temporary voting members may be added for a specific meeting when FDA needs additional expertise or quorum.

A Designated Federal Officer (DFO) manages the federal advisory process for the meeting. A chairperson is not always seated for every session.

What a meeting usually covers

For bulk-substance reviews, FDA staff present their analysis under the agency’s published balancing framework. Nominators and public commenters may speak within the meeting’s time rules. The committee then holds up-or-down recommendation votes — often treating related salt forms (for example, free base and acetate) as a single paired question when the agenda is structured that way.

Non-binding by design

PCAC recommendations inform FDA; they do not replace rulemaking. FDA (and ultimately the Commissioner / HHS leadership within statutory authorities) decides whether to propose and finalize listing. Historical commentary from compounding stakeholders notes that favorable PCAC votes have sometimes stalled for years awaiting proposed or final rules — and that FDA has, at least once, declined to follow a favorable recommendation.

Why process literacy matters

For research organizations following compounding news, the useful skill is reading a meeting as **process**, not as product clearance. Vote tallies describe committee advice. Listing status changes only when FDA completes the regulatory steps that place a substance on Category 1.

*For research use only. Not for human or animal consumption.*